GlassScriptPhysician profile
Brian P Dahl
NPI 1659500718
$31,083.33
in general payments reported to CMS, 2019-2025
20 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $237 · 2021: $3,097 · 2022: $18K · 2023: $7,980 · 2024: $42.91 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,900 · Food and Beverage: $234 · Education: $97.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,900.00 |
| Food and Beverage | $234.42 |
| Education | $97.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lima USA, INC. | $17,583.64 | 2020-2022 | |
| Limacorporate S.P.A. | $11,304.48 | 2021-2023 | Delta Cup |
| Zimmer Biomet Holdings, INC. | $982.39 | 2019-2025 | Persona |
| Stryker Corporation | $425.24 | 2019 | |
| Mml US, INC. | $174.60 | 2021 | |
| Heron Therapeutics, INC. | $110.47 | 2022-2025 | Zynrelef |
| Smith+Nephew, INC. | $95.02 | 2019-2024 | Pico |
| Pfizer INC. | $63.15 | 2020-2024 | |
| Csl Behring | $48.69 | 2020 | |
| Bioventus LLC | $41.44 | 2019 | |
| Innovation Technologies INC | $36.63 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $33.66 | 2023 | Sohonos |
| Sanofi-Aventis U.S. LLC | $31.09 | 2019 | |
| Ethicon US, LLC | $30.99 | 2025 | Stratafix |
| Pacira Therapeutics, INC. | $26.53 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $24.68 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.39 | 2023 | Iovera, Zilretta |
| Amgen INC. | $20.22 | 2019 | |
| Osiris Therapeutics INC. | $14.27 | 2019 | |
| Omeros Corporation | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.